<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/wp-content/plugins/xml-sitemap-feed/assets/sitemap-news.xsl?ver=5.7.7"?>
<!-- generated-on="2026-10-28T21:19:42+00:00" -->
<!-- generator="XML Sitemap & Google News for WordPress" -->
<!-- generator-url="https://status301.net/wordpress-plugins/xml-sitemap-feed/" -->
<!-- generator-version="5.7.7" -->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" >
<url><loc>https://www.medicinanews.it/chirurgia-cataratta-bilaterale-stesso-giorno/369013/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-27T18:30:11+01:00</news:publication_date><news:title>Cataratta bilaterale operata nello stesso giorno: quando è sicura e quali precauzioni adottare</news:title></news:news></url>
<url><loc>https://www.medicinanews.it/farmaci-oncologici-beneficio-clinico-europa/369010/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-27T14:27:09+01:00</news:publication_date><news:title>Farmaci oncologici innovativi: uno studio europeo rivela benefici clinici limitati per la maggior parte delle nuove terapie</news:title></news:news></url>
<url><loc>https://www.medicinanews.it/remibrutinib-sclerosi-multipla-novartis/369007/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-10-27T13:22:20+01:00</news:publication_date><news:title>Il nuovo trattamento Novartis per la sclerosi multipla riduce le ricadute di un terzo secondo gli studi pivot</news:title></news:news></url>
</urlset>
